Emily is the Executive Director of PK/PD at A2-Ai, where she leads a team of scientists that supports industry clients at all stages of the drug development process. She has an extensive background in pharmacometrics and a passion for improving drug development processes and patient outcomes through modeling and simulation. By fostering collaboration with industry partners and regulatory agencies, she aims to shape the future of pharmacometrics and contribute to the development of safe and effective therapies.
Prior to her current position, Emily was a Senior Director of Pharmacometrics at Ann Arbor Pharmacometrics Group (acquired by Amador Bioscience). She holds a PhD in Pharmaceutical Sciences from the University of Michigan, where she has also taught pharmacometrics courses as an adjunct assistant professor.